ArticleQuantitative imaging in medicine and surgery2026
The value of the transthoracic echocardiography score for screening significant coronary artery disease in patients with hypertrophic cardiomyopathy.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery disease (CAD) is common in patients with hypertrophic cardiomyopathy (HCM) and worsens prognosis. We aimed to develop a transthoracic echocardiography score (TTES) to screen for significant CAD in HCM patients. Methods: We conducted a retrospective analysis of 392 patients with HCM concomitant with CAD at Renmin Hospital of Wuhan University. Transthoracic echocardiography assessments and logistic regression analysis were used to derive the TTES. Clinical variables were screened using the least absolute shrinkage and selection operator (LASSO) regression, and the resulting selected features were integrated with TTES for nomogram creation. Results: Among the 392 patients, significant CAD was identified in 106 patients, representing 27.0% of the cohort. TTES was calculated using the following formula: -5.419 + 0.705× (left atrial end-systolic diameter, mm) + 0.114 × (E/e') + 2.583 × (obstruction of left ventricular outflow tract, yes = 1, no = 0). Patients with a high TTES were found to have a greater risk of significant CAD [odds ratio (OR), 6.46, 95% confidence interval (CI): 3.66-11.41, P<0.001]. Additionally, the area under the curve (AUC) of predictive model was 0.755 (TTES: 95% CI: 0.703-0.808; sensitivity: 67.0%, specificity: 68.2%), 0.722 (clinical model: 95% CI: 0.668-0.776; sensitivity: 84.0%, specificity: 55.2%), and 0.834 (TTES + clinical model: 95% CI: 0.791-0.876; sensitivity: 84.0%, specificity: 68.9%). Conclusions: TTES provides a clinically accessible approach integrating routine echocardiographic parameters, enabling noninvasive CAD detection in HCM patients with significant diagnostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.